clinical trial · NCT07743671
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic TelangiectasiaEngasertibPlacebo
brief summary
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.
started
Sep 1, 2026
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Sep 17, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol